UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 69

Sortiert nach

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Journal of clinical oncology, 2010-03, Vol.28 (7), p.1254-1261

2010

Volltextzugriff (PDF)

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2009-10, Vol.101 (19), p.1308-1324

2009

Volltextzugriff (PDF)

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

The New England journal of medicine, 2013-09, Vol.369 (11), p.1023-1034

2013

Volltextzugriff (PDF)

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

The Lancet (British edition), 2014-07, Vol.384 (9940), p.319-328

2014

Volltextzugriff (PDF)

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Nature (London), 2012-06, Vol.486 (7404), p.532-536

2012

Volltextzugriff (PDF)

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Journal of clinical oncology, 2013-02, Vol.31 (6), p.759-765

2013

Volltextzugriff (PDF)

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2013-01, Vol.381 (9863), p.303-312

2013

Volltextzugriff (PDF)

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-12, Vol.26 (35), p.5705-5712

2008

Volltextzugriff (PDF)

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Journal of clinical oncology, 2010-11, Vol.28 (31), p.4697-4705

2010

Volltextzugriff (PDF)

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Cancer research (Chicago, Ill.), 2007-03, Vol.67 (6), p.2643-2648

2007

Volltextzugriff (PDF)

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1626-1634

2008

Volltextzugriff (PDF)

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Clinical cancer research, 2013-04, Vol.19 (7), p.1902-1912

2013

Volltextzugriff (PDF)

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Journal of clinical oncology, 2007-05, Vol.25 (13), p.1658-1664

2007

Volltextzugriff (PDF)

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

The New England journal of medicine, 2004-07, Vol.351 (4), p.337-345

2004

Volltextzugriff (PDF)

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

European urology, 2007-07, Vol.52 (1), p.134-141

2007

Volltextzugriff (PDF)

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

International journal of cancer, 2013-09, Vol.133 (5), p.1259-1265

2013

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3238-3245

2007

Volltextzugriff (PDF)

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Journal of clinical oncology, 2008-04, Vol.26 (10), p.1619-1625

2008

Volltextzugriff (PDF)

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Cancer, 2009-04, Vol.115 (7), p.1544-1554

2009

Volltextzugriff (PDF)

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Journal of clinical oncology, 2005-12, Vol.23 (35), p.8942-8949

2005

Volltextzugriff (PDF)

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Journal of clinical oncology, 2008-11, Vol.26 (33), p.5335-5343

2008

Volltextzugriff (PDF)

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

Journal of clinical oncology, 2000-03, Vol.18 (6), p.1360-1377

2000

Volltextzugriff (PDF)

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Cancer research (Chicago, Ill.), 2009-03, Vol.69 (5), p.1851-1857

2009

Volltextzugriff (PDF)

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

European journal of cancer (1990), 2012-11, Vol.48 (16), p.3082-3092

2012

Volltextzugriff (PDF)

1 – 25 von 69

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

ThemaMedical Sciences

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(68)
Tagungsberichte
(1)

Sprache

Englisch
(69)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Biological And Medical Sciences
(69)
Humans
(64)
Science & Technology
(60)
Life Sciences & Biomedicine
(59)
Oncology
(42)
Tumors
(41)
Male
(37)
Female
(36)
Middle Aged
(35)
Adult
(29)
Aged
(27)
Gastroenterology. Liver. Pancreas. Abdomen
(26)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(26)
Pharmacology. Drug Treatments
(22)
Colorectal Neoplasms - Drug Therapy
(20)
Disease-Free Survival
(18)
Colorectal Neoplasms - Genetics
(17)
Antibodies, Monoclonal - Therapeutic Use
(16)
Treatment Outcome
(16)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies

Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial

Gemcitabine plus Cisplatin versus Gemcitabine plus Carboplatin as First-Line Chemotherapy in Advanced Transitional Cell Carcinoma of the Urothelium: Results of a Randomized Phase 2 Trial

KRAS gene amplification in colorectal cancer and impact on response to EGFR‐targeted therapy

Epidermal Growth Factor Receptor Gene Copy Number and Clinical Outcome of Metastatic Colorectal Cancer Treated With Panitumumab

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

Cell Therapy of Stage IV Nasopharyngeal Carcinoma With Autologous Epstein-Barr Virus–Targeted Cytotoxic T Lymphocytes

Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study

Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy

PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

Aktive Filter

Suchergebnisse filtern